

# Mark A J M Hendriks

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1089493/publications.pdf>

Version: 2024-02-01

5  
papers

118  
citations

1937685

4  
h-index

2053705

5  
g-index

5  
all docs

5  
docs citations

5  
times ranked

196  
citing authors

#	ARTICLE	IF	CITATIONS
1	Bispecific antibody CD73xEpCAM selectively inhibits the adenosine-mediated immunosuppressive activity of carcinoma-derived extracellular vesicles. <i>Cancer Letters</i> , 2021, 521, 109-118.	7.2	12
2	Cancer cells under immune attack acquire CD47-mediated adaptive immune resistance independent of the myeloid CD47-SIRP1 $\alpha$ axis. <i>Oncolmmunology</i> , 2021, 10, 2005344.	4.6	3
3	Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRP1 $\alpha$ $\rightarrow$ eat me $\rightarrow$ immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentation. <i>Oncolmmunology</i> , 2020, 9, 1824323.	4.6	25
4	Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade. <i>Journal of Investigative Dermatology</i> , 2019, 139, 2343-2351.e3.	0.7	20
5	CD20-selective inhibition of CD47-SIRP1 $\alpha$ $\rightarrow$ eat me $\rightarrow$ signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab. <i>Oncolmmunology</i> , 2018, 7, e1386361.	4.6	58